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OBJECTIVES: To collect real-world data on the economic burden and treatment
patterns associated with chronic constipation in Swedish patients through retro-
spective database research.METHODS:A regional Swedish database was used that
combines diagnostic and health care data with prescription drug use and mortality
data from national registers. The drug register comprises all dispensations made at
pharmacies, defined as dispatches. According to Swedish legislation, a dispatch
can last for up to 90 days, which is common for chronic diseases. Adults with
chronic constipation (2 primary constipation diagnoses, or one primary consti-
pation diagnosis and two associated laxative dispatches, over 12 months) were
selected during 2005-2008. Patients with irritable bowel syndrome (IBS) or opioid-
induced constipation were excluded. Data were retrieved on: health care contacts
and drug use for 12 months from the first constipation diagnosis; patient demo-
graphics; and comorbidities. RESULTS: Of the initial selection, 2119 patients were
excluded owing to opioid use (32%) and 435 owing to IBS (7%). The final population
comprised 4043 patients (60% women) with a mean age of 67 years (range: 18-106
years). A history of arrhythmia or diabetes mellitus was common (10%), with
prevalence increasing with age. During follow-up, patients had, on average, 2.3
constipation-related health care contacts and 15.2 additional health care contacts,
at average annual costs of €1642 (standard deviation [SD]: €14 618) and €5944 (SD:
€18 209), respectively. Most patients (54%) used1 type of laxative during follow-up
and 17% used 3 types. On average, patients had four laxative dispatches and 43
non-laxative dispatches, at average annual costs of €61 (SD: €74) and €624 (SD:
€1137), respectively. CONCLUSIONS: Patients with chronic constipation were
mainly elderly with high disease burden, as demonstrated through frequent health
care contacts (17.5/year) and extensive drug use (47 dispatches/year). Constipation-
related care accounted for 22% of total resource utilization, while laxatives made
up 10% of total drug costs.
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OBJECTIVES: Diverticulitis (DV) exerts a significant burden on health care systems
and payers. Although DV is often first diagnosed as an emergent condition in
emergency department (ED) settings, few details on characteristics of DV-related
encounters in ED settings exist. This study characterizes DV-related ED visits in the
US in 2007. METHODS: Data were from the 2007 Healthcare Cost and Utilization
Project (HCUP) Nationwide Emergency Department Sample (NEDS), a nationally
representative sample of ED visits in the US. For each visit in the NEDS, clinical and
resource use information is recorded, including patient demographics, diagnoses
and procedures performed, payer information, and total charges. Patients with a
primary DV diagnosis (ICD-9-CM 562.11 or 562.13) were identified. Patient-, stay-,
and facility-specific characteristics were documented for each DV-related ED visit,
and compared to all ED visits in the US during the same period. Sampling weights
in the NEDS allow for generation of nationally representative estimates. RESULTS:
Of 122.3 million ED visits in the US in 2007, 284,853 involved a primary DV diagno-
sis. Among these visits, mean patient age was 58.3 years, 20 years older than
non–DV-related patients (37.8 years; P0.0001); 55.4% were for female patients.
DV-related visits most often occurred in the southern US (38.1%), private health
insurance was the most frequent payer for these visits (45.6%), and 50% were
admitted to an inpatient facility from the ED (56.7%). The mean charge per DV-
related ED visit (2011 US dollars) was $3,211, nearly double than for non-DV-related
visits ($1,677; P0.0001). Total charges across all DV-related ED visits were $1
billion. CONCLUSIONS: DV requires careful clinical management, across a variety
of health care settings. This study presents novel information on DV-related ED
visits in the US. Adding to the body of knowledge regarding DV-related care may
help providers and decision makers optimize allocation of resources to treat all DV
patients.
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OBJECTIVES: To compare the cost and effectiveness of LacTest® versus other di-
agnostic procedures available to identify lactose intolerance using the perspective
of Spanish National Health System. METHODS: A cost-effectiveness analysis was
carried out using a decision tree comparing LacTest® with the hydrogen breath
test, the capillary blood glucose test and the intestinal biopsy. Data on the effec-
tiveness of each diagnostic procedure, expressed as the sensitivity of each test or
the proportion of true positives identified by the test for all patients, were taken
from the clinical results of the EUDRA study. The use of health care resources
associated with the tests and their costs were obtained from literature review.
Costs considered included diagnostic tests, laboratory tests, physician visits and
time of health care personnel. The time horizon of the analysis was one year. All
costs are expressed in Euro 2012. Results were expressed as the effectiveness and
costs of LacTest® compared with those of the other diagnostic procedures.
RESULTS: The proportion of diagnosed patients, as measured by sensitivity, was
higher for LacTest® with 0.991 than for the other diagnostic procedures with values
of 0.953 for the intestinal biopsy, 0.785 for the hydrogen breath test and 0.748 for the
capillary blood glucose test, respectively. Direct health care costs per patient were
€187 with LacTest®, €143 with the hydrogen breath test, €140 with the capillary
blood glucose test and € 458 for the intestinal biopsy. CONCLUSIONS: The results
indicate that LacTest® is demonstrating a higher sensitivity in the diagnosis of new
cases of hypolactasia compared with the other tests in this study. LacTest®
showed to be the dominant option compared with the intestinal biopsy. When
compared with the hydrogen breath test and the capillary blood glucose test, LacT-
est® showed to be more effective at an incremental cost of €44 and €40, respec-
tively.
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OBJECTIVES: In previously untreated adults with hepatitis C virus (HCV) genotype
1 infection the combination of boceprevir (B) or telaprevir (T) plus peginterferon
alpha/ribavirin (PR) have shown to produce a higher rate of sustained virologic
response (SVR) than peginterferon alfa/ribavirin (PR). The aim of this study is to
assess the cost effectiveness of these two antiviral regimens. METHODS: We de-
veloped a Markov model to describe the clinical history of CHC genotype 1 patients
in which one cohort (1) receives PR for 4 weeks followed by BPR for 24 weeks and
those patients with a detectable HCV RNA level between weeks 8 and 24 receive PR
for an additional 20 weeks; cohort 2 patients receive TPR for 12 weeks followed by
PR for 12 weeks and those patients with a detectable HCV RNA level between weeks
4 and 12 receives PR for an additional 24 weeks. All patients are followed for their
expected lifetime. The reference patient is 30-year-old with CHC without cirrhosis.
The SVRs to BPR and TPR cohorts came from SPRINT 2 and ADVANCE studies.
Quality of life for each health state was based on literature. Costs for each health
state were based on three Delphi panels, one with hepatologists, one with inten-
sivists and another with oncologists. Costs in 2011 Brazilian Reais and benefits
were discounted at 3%. RESULTS: BPR increases life expectancy by 0.78 years and
quality adjusted life years (QALY) by 1.20 years compared to TPR. BPR is cheaper
than TPR (-25,924 Brazilian Reais). CONCLUSIONS: In Brazil, for the treatment of
previously untreated adults with HCV genotype 1 boceprevir plus peginterferon
alpha/ribavirin is dominant compared with telaprevir plus peginterferon alpha/
ribavirin.
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OBJECTIVES:Telaprevir introduced recently as a new protease inhibitor for chronic
HCV infection showed promising results used in conjunction with peginterferon
and ribavirin (triple therapy: TT). We assess the cost-effectiveness of TT compared
to peginterferon-ribavirin dual therapy in the treatment of previously untreated
Japanese patients with genotype1 chronic hepatitis. METHODS: We created a
Markov decision model of HCV natural history and progression toward advanced
liver disease to evaluate the cost-effectiveness of alternative treatment strategies,
in a previously untreated Japanese cohort consisted of patients aged 50 years with
genotype 1 chronic hepatitis for a time horizon of lifetime. We compared 3 strate-
gies; no treatment, standard 48 weeks of dual therapy with further 24 weeks of
extended treatment for late viral responders (DT; total 72 weeks) and 24 weeks of
TT. The data sources of natural history model were mainly derived from Japanese
epidemiological studies. Due to lack of the evidence of the direct comparative
effectiveness between TT and DT in Japanese HCV patients, the results of a ran-
domized control trial compared TT with standard dual therapy was combined with
those of an observational study which compared effectiveness between standard
dual therapy and those with extended treatment. RESULTS: Our model estimated
TT and DT strategies could yield 0.67 and 0.48 of the sustained viral response,
respectively. In the base case analysis, TT was most effective in comparison with
those treated by DT and no treatment strategies and could increase by 0.92 and
2.83 the quality-adjusted life years and reduce the lifetime cost by 1.3 and 0.7
million yen, respectively. This dominance of TT over DTwas robust to sensitivity
analysis. CONCLUSIONS: TT would be more effective and cost-saving strategy
compared with DT for untreated patients chronically infected with HCV of geno-
type 1 in Japan.
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OBJECTIVES: Despite available treatment options, chronic infection of individuals
with the hepatitis C virus (HCV), together with associated chronic liver diseases,
remains a significant public health burden in England and Wales. Fewer than half
of patients with genotype 1 chronic hepatitis C (CHC) achieve sustained virologic
response (SVR) following the current standard treatment with peginterferon alfa
and ribavirin. The aim of this analysis was to evaluate the cost-effectiveness of
boceprevir, a protease inhibitor, in combination with peginterferon alfa and riba-
virin, compared to peginterferon alfa and ribavirin alone, among treatment naïve
and previously treated patients with genotype 1 CHC in England and Wales.
METHODS: Specific treatment strategies for boceprevir have been outlined in the
UK licence for different patient groups. A Markov model was developed to evaluate
these treatment strategies for boceprevir triple-therapy compared to peginterferon
alfa and ribavirin alone, and to estimate the expected costs and health-related
quality of life benefits associated with them. The incremental cost-effectiveness of
including boceprevir in a new triple-therapy standard of care was assessed from
the perspective of the National Health Service and Personal Social Services over the
lifetime of the patient cohort. Clinical data inputs for each treatment strategy were
estimated based on subgroup analyses of the phase III trials for boceprevir.
RESULTS: The incremental cost-effectiveness ratio (ICER) for treatment-naïve pa-
tients was £11,601 when boceprevir triple-therapy was compared to current stan-
dard treatment with peginterferon alfa and ribavirin. For treatment-experienced
patients, the ICER with boceprevir triple-therapy was £2,909. These results were
robust to sensitivity analyses and below a threshold of £20,000. CONCLUSIONS:
The inclusion of boceprevir as part of a new triple-therapy standard of care for
patients with genotype 1 CHC is clinically efficacious and cost-effective, irrespec-
tive of whether patients have been previously treated. The use of boceprevir in this
setting is recommended by NICE.
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OBJECTIVES: Dual therapy with ribavirin and peg-interferon over a duration of
up to 72 weeks (W) has been the former standard of care in patients with chronic
Hepatitis C (HCV) genotype 1 and is still used in some patients. The aim of this
analysis is to evaluate the direct HCV-related costs and effects of dual therapy in
therapy-naïve and pretreated patients in Germany.METHODS: In this retrospec-
tive chart review study, dual therapy in patients with chronic HCV genotype 1 in
2008/2009 was evaluated in Germany. Data from patients treated with a combi-
nation of ribavirin and peg-interferon were retrospectively documented during
the treatment period and thereafter (on average 61 W of post-treatment follow-
up). A total of 208 therapy-naïve and 182 pretreated patients from 31 study sites
were included in the analysis. RESULTS: Mean time since first diagnosis of HCV
was 6.0 years and 10.4 years in therapy-naïve and pretreated patients, respec-
tively. 33.0% of pretreated patients were prior non responders, 37.9% were re-
lapsers. The average treatment duration during study was 42 W (SD 22W) both in
therapy-naïve and pretreated patients. Sustained virological response (SVR)
was demonstrated in 58.1% of therapy naïve and 36.6% of pretreated patients
with HCV-RNA measurements available (167 and 142 patients with measure-
ment, respectively). Mean per patient costs related to HCV during therapy from
the statutory health insurance perspective were 14,554€ (SD 9,139€) for therapy-
naïve and 14,590€ (SD 10,443€) for pretreated patients. Main cost-driver of treat-
ment was medication cost, accounting for 87% of total costs, followed by sick
leaves and diagnostics. Hospitalizations and physician visits played a less im-
portant role in terms of costs. CONCLUSIONS: Especially in pretreated patients,
HCV dual therapy is costly due to the low treatment success rate. This empha-
sizes the need for treatments with improved efficacy, minimizing costly non-
response resulting in potential cost savings.
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OBJECTIVES: To assess cost-effectiveness of adalimumab versus standard care
(SC) for treating patients with severely active Crohn’s disease (CD) in Germany
from a societal perspective. Additionally, cost-per-remitter for adalimumab was
estimated and compared with infliximab 5mg/kg maintenance therapy.
METHODS: To compare adalimumab to SC, a 4-disease-state clinical model (ie,
remission, moderate, severe, very severe) based on the Crohn’s Disease Activity
Index (CDAI) was constructed tracking patients over their lifetimes. The model
estimated direct costs, indirect costs, and quality-adjusted life-years (QALYs)
from the German societal perspective. Efficacy inputs for adalimumab were
based on actual observations from CHARM (Crohn’s Trial of the Fully Human
Antibody Adalimumab for Remission Maintenance). Using data from CLASSIC I
(Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction
Therapy in Crohn’s Disease), a regression model was used to predict efficacy of
SC. Direct/indirect costs and utility inputs were derived from public sources and
literature. To compare adalimumab to infliximab, cost-per-remitter was esti-
mated by dividing costs by the percentage of patients in remission on a yearly
basis. Remission rates of adalimumab and infliximab upon baseline matching
adjustment for patients with moderate-to-severe CD came from CHARM and
ACCENT I (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-
Term Treatment Regimen), respectively. RESULTS: The incremental costs per
QALY gained for adalimumab versus SC were €37,270 (2012 Euro) over a lifetime
horizon in the base case. One-way sensitivity analyses varying key parameters
produced incremental costs per QALY gained ranging from €23,011–€51,528
when compared with SC. An average of 47.2% adalimumab-treated and 37.1%
infliximab-treated patients were in remission yearly. The corresponding cost-
per-remitter was €54,823 for adalimumab and €88,506 for infliximab.
CONCLUSIONS: Adalimumab appears to be cost-effective compared with SC for
treating patients with severely active CD. The cost-per-remitter for mainte-
nance therapy was less for adalimumab than for infliximab.
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OBJECTIVES: In patients with chronic infection with hepatitis C virus (HCV) geno-
type 1 who did not achieve a sustained response to the standard therapy with
peginterferon/ribavirin (PR) the combination of boceprevir (B) or telaprevir (T) plus
peginterferon alpha/ribavirin have shown to produce a higher rate of sustained
virologic response (SVR) than the retreatment with PR. The aim of this study is to
assess the cost effectiveness of these two (BPR and TPR) antiviral regimens.
METHODS: We developed a Markov model to describe the clinical history of previ-
ously treated HCV genotype 1 patients who did not achieve SVR in which one
cohort (1) receives PR for 4 weeks followed by BPR for 32 weeks and, those patients
with a detectable HCV RNA level at week 8 receive PR for an additional 12 weeks;
cohort 2 patients receive 12 weeks TPR followed by 36 weeks PR. All patients are
followed for their expected lifetime. The reference patient is 30-year-old with CHC
without cirrhosis. The SVRs to BPR and TPR cohorts came from RESPOND 2 and
REALIZE studies. Quality of life for each health state was based on literature. Costs
for each health state were based on three Delphi panels, one with hepatologists,
one with intensivists and another with oncologists. Costs in 2011 Brazilian Reais
and benefits were discounted at 3%. RESULTS: The combination BPR increases life
expectancy by 0.60 years and quality adjusted life years (QALY) by 0.89 years com-
pared to TPR. BPR is cheaper than TPR (-23,428 Brazilian Reais). CONCLUSIONS: In
Brazil, for the treatment of previously treated patients with HCV genotype 1 infec-
tion boceprevir plus peginterferon alpha/ribavirin is dominant compared with te-
laprevir plus peginterferon alpha/ribavirin.
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OBJECTIVES: The study compares the cost-effectiveness (CE) of dexlansoprazole
with other proton pump inhibitors (PPI) currently included in the Mexico National
Formulary (Positive List) for treatment of erosive esophagitis (EE). METHODS: A
decision tree with the 8-week temporal horizon was designed for patients over 18
with EE confirmed by endoscopy. The perspective taken is that of second-level
public health institutions. Treatment alternatives modelled are dexlansoprazole 60
mg/day, esomeprazole 40 mg/day; omeprazole 20 mg/day, pantoprazole 40mg/day,
rabeprazole 20 mg/day. Possible outcomes considered were healing or not healing,
the latter possibly leading to surgery. Costs included in the model were treatment
regimens, consult, endoscopy, surgery (when necessary), and hospitalization days
(when necessary) and were taken from official or published sources. Effectiveness
was measured in terms of percentage of patients with healed oesophagus. A
weighted average of effectiveness was calculated for use in the model. One-way
sensitivity analyses of cost and effectiveness variables and a Monte Carlo (MC)
simulation of a 1000 cohorts were also conducted to test the robustness of the
results. RESULTS: Compared to all PPIs modelled/tested, dexlansoprazole was
highly dominant, being more effective (0.9270) and less costly (USD$ 1.27 per day),
even when compared to omeprazole’s USD$ 0.015 per DDD. It was therefore not
considered necessary to calculate the Incremental Cost-Effectiveness Ratio (ICER)
since these would be negative. The sensitivity analyses and Monte Carlosimula-
tions found omeprazole to be the second-best alternative, and actually dominant
in 16.7% of the MC simulations. CONCLUSIONS: Dexlansoprazole was found to be
dominant compared to all PPIs evaluated for EE, being both more effective and less
costly for public institutions in Mexico.
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COST-EFFECTIVENESS OF EPISODIC OR MAINTENANCE INFLIXIMAB VERSUS
STANDARD TREATMENT IN AN INCIDENCE COHORT OF CROHN’S DISEASE
PATIENTS WITH 10-YEARS FOLLOW-UP
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